Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3).
Yuan-Kai ShiLin WuXinmin YuPuyuan XingYan WangJianying ZhouAirong WangJianhua ShiYi HuZiping WangGuangyu AnYong FangSanyuan SunCai-Cun ZhouChangli WangFeng YeXingya LiJunye WangMengzhao WangYunpeng LiuYanqiu ZhaoYing YuanJifeng FengZhendong ChenJindong ShiTao SunGang WuYongqian ShuQisen GuoYi ZhangYong SongShucai ZhangYuan ChenWei LiHongrui NiuWenwei HuLijun WangJianan HuangYang ZhangYing ChengZhengdong WuBo PengJiya SunChristoph MancaoYanqi WangLuyao SunPublished in: Cancer communications (London, England) (2022)
Compared with docetaxel, sintilimab significantly improved the OS, PFS, and ORR of Chinese patients with previously treated locally advanced or metastatic sqNSCLC.